Abstract | OBJECTIVE: PATIENTS AND METHODS: Between August 2005 and March 2008, we conducted a prospective, two-arm, cluster observational study, in which participating hospitals were pre-registered either to the nifekalant arm or the lidocaine arm. Patients were enrolled if they had in-hospital VF or VT resistant to at least two defibrillation shocks. Congenital or drug-induced long QT syndrome was excluded. The primary end-point was termination of VF or VT with/without additional shock. The secondary end-points were return of spontaneous circulation (ROSC), 1-month survival and survival to hospital discharge. We also assessed the frequency of adverse events, including asystole, pulseless electrical activity and torsade de pointes. RESULTS: In total, 55 patients were enrolled. After nifekalant, 22 of 27 patients showed termination of VF or VT, as compared with 15 of 28 patients treated with lidocaine with/without additional shock (odds ratio (OR): 3.8; 95% confidence interval (CI): 1.1-13.0; P=0.03). Twenty-three of 27 patients given nifekalant showed ROSC, as compared with 15 of 28 patients given lidocaine (OR: 5.0; 95% CI: 1.4-18.2; P=0.01). There was no difference in 1-month survival or survival to hospital discharge between the nifekalant and lidocaine arms. There was a higher incidence of asystole with lidocaine (7 of 28 patients) than with nifekalant (0 of 27 patients) (P=0.005). Torsade de pointes was not observed. CONCLUSION:
Nifekalant was more effective than lidocaine for termination of arrhythmia and for ROSC in patients with shock-resistant in-hospital VF or VT (umin-CTR No. UMIN 000001781).
|
Authors | Tsuyoshi Shiga, Keiji Tanaka, Rinya Kato, Mari Amino, Yuji Matsudo, Toshihiro Honda, Koichi Sagara, Atsushi Takahashi, Takao Katoh, Mitsuyoshi Urashima, Satoshi Ogawa, Teruo Takano, Hiroshi Kasanuki, Refractory VT/VF, Prospective Evaluation to Differentiate Lidocaine Efficacy from Nifekalant (RELIEF) Study Investigators |
Journal | Resuscitation
(Resuscitation)
Vol. 81
Issue 1
Pg. 47-52
(Jan 2010)
ISSN: 1873-1570 [Electronic] Ireland |
PMID | 19913983
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2009 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Anti-Arrhythmia Agents
- Pyrimidinones
- nifekalant
- Lidocaine
|
Topics |
- Aged
- Anti-Arrhythmia Agents
(therapeutic use)
- Chi-Square Distribution
- Female
- Humans
- Lidocaine
(therapeutic use)
- Male
- Middle Aged
- Prospective Studies
- Pyrimidinones
(therapeutic use)
- Statistics, Nonparametric
- Survival Rate
- Tachycardia, Ventricular
(drug therapy, physiopathology, therapy)
- Treatment Outcome
- Ventricular Fibrillation
(drug therapy, physiopathology, therapy)
|